In this study, acute administration of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide to mice increased the cecal levels of caseinolytic protease B, a component of Escherichia coli , and of norepinephrine
Some individuals may experience mild, temporary symptoms such as stomach upset or changes in bowel habits
Long-term success for patients taking GLP-1s likely looks like patient-centered care programs where individuals arent just receiving the drug but are also placed within a supportive framework that can monitor their health and adjust treatments or approaches as needed
In the first week, the main goal is to help your body tolerate the medication
It wastes time, delays results, and in some cases puts your health at risk
Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse